Understand the source comparison
Peptides for Androgenetic Alopecia Research Compared: Study Design Comparison
Copper Peptides (GHK-Cu) Upregulates lysyl oxidase for collagen cross-linking; removes perifollicular fibrosis Topical solution 1–2% concentration applied daily 6–12 months +3–5% hair density, no significant change in follicle count +12–18% improvement in shaf
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Copper Peptides (GHK-Cu)
- Upregulates lysyl oxidase for collagen cross-linking; removes perifollicular fibrosis
- Topical solution 1–2% concentration applied daily
- 6–12 months
- +3–5% hair density, no significant change in follicle count
- +12–18% improvement in shaft thickness when combined with minoxidil
- GHK-Cu enhances existing treatment response by improving dermal matrix. It is not a hair growth agent on its own
- Thymosin Beta-4 Fragments (TB4-Frag)
- Stimulates VEGF expression to rebuild perifollicular capillary network
- Subcutaneous injection 500–750µg per session, weekly
- 4–6 months
- No measurable change in hair count or density
- +15–20% increase in perifollicular blood flow; extends anagen phase in miniaturized follicles already responding to DHT blockade
- TB4-Frag addresses the vascular deficit that limits other treatments. Requires injection, not topical application
- Decapeptide-12
- Inhibits TGF-β1 signaling to prevent follicular fibrosis and irreversible scarring
- Topical solution or microneedling-assisted delivery, twice weekly
- 12–16 months
- Preserves follicle structure but does not restart growth; no density increase
- Prevents progression from miniaturization to permanent loss in patients discontinuing finasteride
- Decapeptide-12 halts terminal-stage scarring. Valuable for treatment maintenance, not hair regrowth
- Minoxidil 5% (comparator)
- Opens ATP-sensitive potassium channels to prolong anagen phase directly
- Topical solution applied twice daily
- 12 months standard
- +18–22% increase in non-vellus hair count vs baseline
- N/A. Minoxidil is first-line therapy
- Gold standard topical treatment; peptides do not replicate this mechanism
- Finasteride 1mg (comparator)
- Inhibits Type II 5-alpha-reductase to reduce scalp DHT by ~70%
- Oral tablet daily
- 12 months minimum
- +24–28% increase in hair count; halts further miniaturization in 80–85% of users
- N/A. Finasteride is first-line therapy
- Only systemic DHT blocker with Level 1 evidence for AGA; peptides do not replicate this mechanism